EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy

Source: EyeGate Pharmaceuticals

Wednesday, November 01, 2017 | Management/Leadership , Eyegate Pharmaceuticals


EyeGate Pharmaceuticals has appointed Mike Garanzini as Chief Commercial Officer, effective immediately. Mr. Garanzini will be responsible for developing and implementing the global launch and commercialization strategy for Eyegate’s pipeline of product candidates.

“As we prepare to transition from a clinical to commercial organization, the need to accelerate development of the launch plan became clear,” Stephen From, President and Chief Executive Officer of EyeGate, said in a company news release. “We are fortunate to have landed Mike for this very important role and look forward to supporting his efforts.”

Mr. Garanzini has more than 25 years of marketing experience in the pharmaceutical industry. Prior to joining EyeGate, he was the Global Marketing Therapy Leader for the Glaucoma Portfolio at Santen, where he was responsible for providing strategic direction to advance glaucoma products, including the acquisition and integration of the InnFocus MicroShunt. Prior to assuming that role, Mr. Garanzini served as Santen’s Head of Marketing, Europe where he played a key role in the integration of the Merck Ophthalmic products, establishing operations throughout Western Europe and ultimately led the total portfolio of glaucoma, dry eye and retinal disease products. Previously, Mr. Garanzini was the Senior Director of Global Marketing, Ophthalmology at Merck, where he was in charge of overseeing strategic planning, medical education, opinion leader relations and co-promotion alliances on a global basis while also having specific geographical responsibility for Europe. Earlier in his career at Merck, Mr. Garanzini held two non-ophthalmic product-specific roles, as U.S. Director of Marketing for Levitra and Asmanex in the Primary Care markets where he gained important DTC experience. Mr. Garanzini has also held sales and marketing positions in Pharmacia’s ophthalmology division, where he was part of the team responsible for the launch and growth phase of Xalatan and time managing surgical products used in cataract and glaucoma surgery. Mr. Garanzini holds a B.S. in Engineering from Michigan State University.

“EyeGate’s pipeline of ophthalmological treatments have the potential to solve numerous problems in eye care, providing significant benefit to patients in need,” commented Mr. Garanzini. “I am thrilled to be a part of EyeGate as the company enters an exciting phase of growth and expansion and I look forward to developing a strategy to bring these product candidates to market.”


Comments

You must be logged in to leave a comment.